You searched for "diagnostic"

501 results found

Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase

Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...

The case against omitting systematic biopsy in younger men

In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...

Prostate cancer: Black men more likely to be diagnosed at later stages

Latest data shows Black men have higher rates of stage 3 or stage 4 prostate cancer diagnoses compared with white men. Black men diagnosed at a later stage in their 60s are 14% less likely to get NICE approved treatment...

Prostate cancer series: diagnostics 1

- Click here for Part 2 - A 58-year-old male is referred to your rapid access prostate clinic with a prostate specific antigen (PSA) of 6.0ng/ml. He has no lower urinary tract symptoms (LUTS), past medical history (PMH), or family...

Prostate Cancer UK: PSA Consensus Conference 2024

During the conference, you'll get up-to-date information on the latest consensus regarding the PSA blood test. You'll also be able to discuss the diagnostic process for secondary care and learn how to proactively manage conversations about prostate health with patients who are at higher risk. You’ll have plenty of opportunities to ask questions, interact with peers, and apply what you learn through engaging case studies. 9am – 12.30pm

Prostate cancer and an electronic nose

So far the transrectal ultrasound guided (TRUS) biopsy has been the ‘gold standard’ for diagnosing prostate cancer. However, it is invasive and can lead to complications, so there is a need for new non-invasive diagnostic tools to avoid unnecessary biopsy...

Small renal masses – diagnosis and management

Renal cancer is the eighth most common cancer in the UK and accounts for about 3% of all new cancer diagnoses [1]. The incidence rates are steadily rising, with the highest rates being in older men and women. This rise...

A laboratory in your pocket

In this series of articles, I show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk) and in this one I am joined by Mary Garthwaite, retired urologist and Chair of The...

Challenges of upper tract urothelial carcinoma

Upper tract uroepithelial carcinoma (UTUC) is a fairly common disease which traditionally had poorer outcomes compared to bladder cancer. This is due to various factors leading to delayed diagnosis and problems in risk stratification. Continuing efforts have focused on early...

Biomarkers in prostate cancer detection

Prostate cancer (PCa) is the second most common cancer in men with an estimated prevalence of 1.1 million worldwide in 2012. This heterogeneous disease resulted in approximately 307,000 deaths, making it the fifth leading cause of cancer-related death in men...

Dogs and humans share a bladder cancer biomarker: a new discovery that opens doors for early detection and treatment

A new scientific study has identified a new molecular biomarker that could help doctors detect aggressive early-stage bladder cancer, such as high-grade non-muscle invasive bladder cancer (NMIBC), in both dogs and humans. This discovery advances our knowledge of how aggressive...